BACKGROUND Rheumatoid arthritis is a long-term, progressive autoimmune disease. It is characterized by synovial hyperplasia leading to swelling, stiffness, and joint deformity in more than one joint. Fibroblast-like synoviocytes are the major cell types that make up the synovial intima structure, which is one of the decisive factors in the development and course of rheumatoid arthritis. METHODS The potential therapeutic effects of MSCs-derived miRNA-124a overexpression exosomes were evaluated in vitro by the method including MTT assay and cell cycle test for cell proliferation, scratch wound closure and transwell for cell migration, flow cytometry and western for the apoptosis detection. RESULTS Exosomes derived from human MSCs that overexpression miRNA-124a were prepared and characterized. We found that the pretreatment of this exosome was able to inhibit the proliferation and migration of fibroblast-like synoviocyte cell line and promote the apoptosis of this cell during the co-incubation. CONCLUSIONS Exosomes derived from MSCs were proved to be a suitable vector for the delivery of therapeutic miRNA-124a, and such miRNA-124a overexpression exosomes were expected to provide a new medicine and strategy for the treatment of rheumatoid arthritis.

中文翻译：

---

人类MSCs衍生的miRNA-124a过表达外来体对类风湿关节炎相关成纤维细胞样滑膜细胞增殖和迁移的抑制作用。

背景技术类风湿关节炎是一种长期的，进行性自身免疫疾病。它的特征是滑膜增生，导致多个关节肿胀，僵硬和关节变形。成纤维样滑膜细胞是组成滑膜内膜结构的主要细胞类型，滑膜内膜结构是类风湿关节炎发展和进程中的决定性因素之一。方法采用MTT法和细胞周期试验对细胞增殖，刮伤闭合和transwell进行细胞迁移，流式细胞术，western法进行细胞凋亡检测。结果制备并表征了来自人MSC的外表达miRNA-124a。我们发现该外泌体的预处理能够抑制成纤维样滑膜细胞系的增殖和迁移，并在共同孵育过程中促进该细胞的凋亡。结论事实证明，源自MSC的外泌体是用于递送治疗性miRNA-124a的合适载体，并且预期这种miRNA-124a过表达外泌体将为类风湿性关节炎的治疗提供新的药物和策略。